NOVO — Marts 2026
-
-
DNB Carnegie lowers its price target on $NVO to DKK 420 (from DKK 430) and reiterates its Buy rating.
-
BLA resubmission and U.S. launch, following approval, expected in 2026. A meeting between FDA and Catalent Indiana occurred early in the first quarter of 2026. The meeting was constructive and included a discussion of Novo Nordisk’s progress remediating the Catalent Indiana facility. No additional corrective actions were requested by FDA. Scholar Rock plans to resubmit the apitegromab BLA following a successful reinspection of the site. Så fabrikken skulle gerne snart være oppe at køre
-
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports https://www.reuters.com/business/healthcare-pharmaceuticals/roche-targets-double-digit-market-share-weight-loss-aims-catch-up-with-novo-2026-03-03/
-
Medie: Hims & Hers-partner lufter tanker om at genintroducere kopi af Wegovy-pille https://borsen.dk/nyheder/virksomheder/medie-hims-hers-partner-lufter-tanker-om-at-genintroducere-kopi-af-wegovy-pille Link til originalartikel: https://endpoints.news/hims-partner-strive-pharmacy-will-reintroduce-glp-1-pill-pulled-from-market/
-
FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s
-
“Novo: Hims & Hers-partner afviser planer om at genintroducere kopi af Wegovy-pille - NY” https://www.sydinvest.dk/nyheder/novo-hims-hers-partner-afviser-planer-om-at-genintroducere-kopi-af-wegovy-pille-ny
-
Asien: Mellemøstkonflikt udløser paniksalg - Seoul dropper 10 pct https://proinvestor.com/investornyt/1417318/asien-mellemostkonflikt-udloser-paniksalg-seoul-dropper-10-pct
-
Asien/Aktier: Det ligner paniksalg i Sydkorea https://proinvestor.com/boards/131407/
-
Marketwire: FDA SENDER NYE ADVARSLER TIL KOPIPRODUCENTER AF NOVOS MEDICIN
De amerikanske sundhedsmyndigheder FDA har tirsdag sendt advarselsbreve til 30 selskaber for vildledende markedsføring af vægttabsmedicin. Det sker efter produkterne, som efterligner Novos medicin med det aktive stof Semaglutid kendt fra Ozempic og Wegovy, blev fejlagtigt præsenteret som FDA-godkendte.
-
Novo får endnu et brev fra FDA om "misvisende" reklame - denne gang for Ozempic https://proinvestor.com/investornyt/1417329/novo-far-endnu-et-brev-fra-fda-om-misvisende-reklame-denne-gang-for-ozempic
-
Novo lægger sig i toppen af C25: FDA har "skruet op for varmen" for kopister siger Citi https://proinvestor.com/investornyt/1417389/novo-laegger-sig-i-toppen-af-c25-fda-har-skruet-op-for-varmen-for-kopister-siger-citi
-
Alberto, meget enig i at de går efter API besparelser, og bedre gennemsnitlig effekt gennem stabilt optag. Og så den store strategiske ting, at gøre det til en ukompliceret pille uden forbehold for hvornår du må tagen den. Super vigtigt i så stort et markede. Den skal kunne sælges på statin niveauer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind